{
  "id": "6440306357b1c7a315000046",
  "type": "list",
  "question": "What were the primary endpoints of the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich's ataxia patients?",
  "ideal_answer": "The primary endpoints of the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich's ataxia patients were safety, tolerability, and pharmacokinetic analysis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
  ],
  "snippets": [
    {
      "text": "To evaluate the safety, pharmacokinetics, and preliminary efficacy of RT001 in Friedreich's ataxia patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The primary endpoints were safety, tolerability, and pharmacokinetic analysis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "safety, tolerability, pharmacokinetic analysis"
}